Related Experiment Video
Updated: Jun 14, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML
Xiao-Wei Zhang1, Xiao-Jing Yan, Zi-Ren Zhou
1State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai 200025, China.
Abstract:
Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As2O3) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RARalpha (a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor alpha). PML and PML-RARalpha degradation is triggered by their SUMOylation, but the mechanism by which As2O3 induces this posttranslational modification is unclear. Here we show that arsenic binds directly to cysteine residues in zinc fingers located within the RBCC domain of PML-RARalpha and PML. Arsenic binding induces PML oligomerization, which increases its interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme UBC9, resulting in enhanced SUMOylation and degradation. The identification of PML as a direct target of As2O3 provides new insights into the drug's mechanism of action and its specificity for APL.
Insights
Arsenic trioxide (As2O3) treats acute promyelocytic leukemia (APL) by targeting the PML-RARalpha oncogenic protein. This study reveals arsenic directly binds PML, enhancing its SUMOylation and degradation, offering new therapeutic insights.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Arsenic trioxide (As2O3) is a promising anticancer agent, particularly for acute promyelocytic leukemia (APL).
- As2O3 promotes the degradation of the oncogenic PML-RARalpha fusion protein in APL cells.
- The precise mechanism by which As2O3 induces PML-RARalpha degradation via SUMOylation remains unclear.
Purpose of the Study:
- To elucidate the molecular mechanism by which arsenic trioxide (As2O3) induces the degradation of PML and PML-RARalpha.
- To identify the direct molecular target of As2O3 within the PML protein.
Main Methods:
- Investigated the direct binding of arsenic to PML and PML-RARalpha proteins.
- Utilized techniques to assess protein-protein interactions and posttranslational modifications, specifically SUMOylation.
- Analyzed the effect of arsenic binding on PML oligomerization and its interaction with UBC9.
Main Results:
- Demonstrated that arsenic directly binds to cysteine residues within the zinc fingers of the PML RBCC domain.
- Showed that arsenic binding induces PML oligomerization.
- Confirmed that arsenic-induced PML oligomerization enhances its interaction with UBC9, leading to increased SUMOylation and subsequent degradation.
Conclusions:
- PML is a direct molecular target of arsenic trioxide (As2O3).
- Arsenic binding to PML is the critical initiating event for enhanced SUMOylation and degradation of PML and PML-RARalpha.
- This provides a mechanistic explanation for the specificity and efficacy of As2O3 in treating APL.
Related Concept Videos
Abnormal Proliferation
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Regulation of Nuclear Protein Sorting
Negative Regulator Molecules
